A counterfeit version of the injectable cancer drug bevacizumab that may contain no active ingredient has been distributed to clinics in the United States, according to a US Food and Drug Administration (FDA) alert to physicians. The incident is the latest in a string of cases in which foreign drug distributors have sold counterfeit medications to US medical practices.
According to the warning (http://tinyurl.com/ael9nwu), a US company calling itself Medical Device King (also known as Pharmalogical) distributed 2 batches of a counterfeit version of bevacizumab labeled as Altuzan. The counterfeits were labeled as Altuzan, 400 mg/16 mL, and had batch numbers B6022B01 (which bear an expiration date of November 2013) and B6024B01 (with an expiration date of February 2013).
Kuehn BM. FDA Warning: New Batch of Fake Bevacizumab Found. JAMA. 2013;309(9):864. doi:10.1001/jama.2013.1719
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: